Journal of Autism and Developmental Disorders

, Volume 31, Issue 1, pp 103–108 | Cite as

Brief Report: Case Reports on Naltrexone Use in Children with Autism: Controlled Observations Regarding Benefits and Practical Issues of Medication Management

  • Patricia Gail Williams
  • AnnaMary Allard
  • Lonnie Sears
  • Nancy Dalrymple
  • Allen S. Bloom
Article

Keywords

Medication Management Naltrexone Practical Issue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Abidin, R. R. (1995). Parenting Stress Index. Odessa, FL: Psychological Assessment Resources.Google Scholar
  2. Achenbach, T. M. (1991). Manual for the Child Behavior Checklist and 1991 Profile.Burlington: University of Vermont Department of Psychiatry.Google Scholar
  3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders(4th ed.). Washington, DC: Author.Google Scholar
  4. Bailey, A., Phillips, N., Rutter, M. (1996). Autism: Towards an integration of clinical, genetic, neuropsychological and neurobiological perspectives. Journal of Child Psychology and Psychiatry, 3789-126.Google Scholar
  5. Barrett, R. P., Feinstein, C., & Hole, W. T. (1989). Effects of naloxone and naltrexone on self injury: a double-blind, placebocontrolled analysis. American Journal of Mental Retardation, 93644-51.Google Scholar
  6. Borghese, I. F., Herman, B. H., Asleson, G. S., Chantoor, I., Benoit, M. B., Papero, P., & McNulty, G. (1991). Effects of acutely administered naltrexone on social behaviors of autistic children. Society for Neuroscience abstracts, 21st Annual Meeting. Google Scholar
  7. Bouvard, M., Leboyer, M., Launay, J., Recasen, C., Plunet, M. H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., & Panksepp, J. (1995). Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a doubleblind, placebo-controlled study. Psychiatry Research, 58191-201.Google Scholar
  8. Campbell, M. (1996). Resolved: Autistic children should have a trial of naltrexone. Journal of the American Academy of Child and Adolescent Psychiatry, 35246-247.Google Scholar
  9. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 321283-1291.Google Scholar
  10. Chamberlain, R. S., & Herman, B. H. (1990). A novel biochemical model linking dysfunctions in brain melatonin, propio melanin cortin peptides and serotonin in autism. Biological Psychiatry, 28773-793.Google Scholar
  11. Gillberg, C. (1995). Endogenous opioids and opioid antagonists in autism: brief review of empirical findings and implications for clinicians. Developmental Medicine and Child Neurology, 37239-245.Google Scholar
  12. Gilliam, J. E. (1995). Gilliam Autism Rating Scale.Austin, TX: ProEd.Google Scholar
  13. Harris, J. C. (1996). Negative. Journal American Academy of Child and Adolescent Psychiatry, 35248-249.Google Scholar
  14. Herman, B. H., Hammock, M. K., & Arthur-Smith, A. (1986). Role of opioid peptides in autism: Effects of acute administration of naltrexone. Society of Neuroscience, Abstracts, 121172.Google Scholar
  15. Kolmen, B., Feldman, H., Harden, B., & Janosky, J. (1997). Naltrexone in young autistic children: Replication study and learning measures. Journal of the American Academy of Child and Adolescent Psychiatry, 361570-1578.Google Scholar
  16. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: A revised version of the autism diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24659-685.Google Scholar
  17. National Institutes of Health. (1995). An NIH State of the Science Conference(reprint).Google Scholar
  18. Panksepp, J. (1979). A neurochemical theory of autism. Trends in Neurosciences, 2174-177.Google Scholar
  19. Rutter, M., Bailey, A., Button, P., LeCouteur, A. (1994). Autism and known medical conditions: myth and substances. Journal of Child Psychology and Psychiatry, 35311-322.Google Scholar
  20. Schopler, E., Reichler, R. J., & Renner, B. R. (1988). The Childhood Autism Rating Scales(CARS). Los Angeles: Stern Psychological Services.Google Scholar
  21. Willemsen-Swinkels, S. H. N., Buitelaar, J., & van Engeland, H. (1996). The effects of chronic naltrexone treatment in young children: A double-blind, placebo-controlled crossover study. Biological Psychiatry, 391023-1031.Google Scholar
  22. Willemson-Swinkels, S. H. N., Buitelaar, J. K., van Berckelaer-Onnes, L. A., & van Engeland, H. (1999). Six months continuation treatment in naltrexone-responsive children with autism: An open-label case-control design. Journal of Autism and Developmental Disorders, 29167-169.Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Patricia Gail Williams
    • 1
  • AnnaMary Allard
    • 1
  • Lonnie Sears
    • 1
  • Nancy Dalrymple
    • 1
  • Allen S. Bloom
    • 1
  1. 1.University of LouisvilleLouisville

Personalised recommendations